We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Group May Affect Heart Attack Risk

By LabMedica International staff writers
Posted on 18 May 2017
Print article
Healthcare professionals should consider a person's blood group when assessing their cardiovascular risk as people with A, B, and AB blood types may be at greater risk of cardiovascular events, particularly heart attacks, than individuals with O blood types.

There are some risk factors for heart attack that can be addressed, such as a poor diet, lack of exercise, and smoking. However, some heart attack risk factors cannot be changed, such as age, gender, and a family history of heart disease. A new study suggests that blood type should be added to the list.

Scientists at the University Medical Centre Groningen conducted a meta-analysis of studies that reported participants' blood types and the incidence of cardiovascular events, including heart attack, heart disease, heart failure, and cardiovascular death. The data included more than 1.3 million adults who were a part of 11 cohorts across nine studies. The investigators used the data to assess how each blood group might impact the risk of coronary events, combined cardiovascular events, and fatal coronary events.

The team identified 771,113 individuals with a non-O blood group and 519,743 individuals with an O blood group in the analysis of all coronary events. Among people with a non-O blood group, 1.5% (11,437) experienced a coronary event, compared with 1.4% (7,220) of people with an O blood group. In the analysis of combined cardiovascular events, they identified 708,276 people with a non-O blood group and 476,868 people with an O blood group. Among individuals with a non-O blood group, 2.5% (17,449) experienced a cardiovascular event, compared with 2.3% (10,916) who had an O blood group.

The scientists noted the that individuals with non-O blood types have higher concentrations of a blood-clotting protein called von Willebrand factor, which previous studies have linked to thrombotic events. Additionally, they point out that people with non-O blood groups, especially those with an A blood type, tend to have higher cholesterol levels, which is a known risk factor for poor cardiovascular health. The odd ratio (OR) for combined cardiovascular events was significantly higher in non-O blood group carriers, at 1.09 (95% CI 1.06-1.11).

Tessa Kole, a Master's degree student and lead author of the study said, “We demonstrate that having a non-O blood group is associated with a 9% increased risk of coronary events and a 9% increased risk of cardiovascular events, especially myocardial infarction. In future, blood group should be considered in risk assessment for cardiovascular prevention, together with cholesterol, age, sex, and systolic blood pressure.” The study was presented at the annual meeting of the European Society of Cardiology, held April 29 to May 2, 2017, in Paris, France.

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.